Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study

Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use – a post hoc analysis of the ReLiAM study

Abstract Background ReLiAM, Real-Life Assessment of Abilify Maintena, was the first reported long-term prospective non-interventional study for patients with schizophrenia treated with aripiprazole once-monthly injectable formulation (AOM) under real-life conditions. ReLiAM’s primary aim was to eval...

Full description

Bibliographic Details
Main Authors: Howard C. Margolese, Matthieu Boucher, Francois Therrien, Guerline Clerzius
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Psychiatry
Subjects:
Aripiprazole
Injectable
Monthly
Schizophrenia
Substance use
Online Access:https://doi.org/10.1186/s12888-022-04397-x

Internet

https://doi.org/10.1186/s12888-022-04397-x

Similar Items